Monopar Therapeutics (MNPR) Accounts Payables (2016 - 2025)

Monopar Therapeutics (MNPR) has 10 years of Accounts Payables data on file, last reported at $2.7 million in Q4 2025.

• For the quarter ending Q4 2025, Accounts Payables rose 21.33% year-over-year to $2.7 million; the trailing twelve-month figure through Dec 2025 stood at $2.7 million (up 21.33% YoY), and the FY2025 full-year result was $2.7 million, up 21.33% from the prior year.
• Accounts Payables climbed to $2.7 million in Q4 2025, from $2.6 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $3.1 million in Q4 2022 to a low of $806272.0 in Q1 2021.
• A 5-year average of $1.8 million and a median of $1.7 million in 2023 frame the typical range for Accounts Payables.
• Across the five-year window, Accounts Payables surged 253.12% in 2021 and sank 56.45% in 2024, its largest moves.
• Tracing MNPR's Accounts Payables over 5 years: stood at $1.6 million in 2021, then jumped by 97.96% to $3.1 million in 2022, then plunged by 43.83% to $1.8 million in 2023, then grew by 28.28% to $2.3 million in 2024, then increased by 21.33% to $2.7 million in 2025.
• Business Quant data shows MNPR's Accounts Payables at $2.7 million in Q4 2025, $2.6 million in Q3 2025, and $1.6 million in Q2 2025.